Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti- Synthetase Auto-Antibodies: An Open-Label, Phase II Trial.

Date publication

janvier 2015

Journal

PloS one

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DEVILLIERS Hervé

Tous les auteurs :
Allenbach Y, Guiguet M, Rigolet A, Marie I, Hachulla E, Drouot L, Jouen F, Jacquot S, Mariampillai K, Musset L, Grenier P, Devilliers H, Hij A, Boyer O, Herson S, Benveniste O

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26539981

Résumé

Anti-synthetase syndrome (anti-SS) is frequently associated with myositis and interstitial lung disease (ILD). We evaluated prospectively, in a multicenter, open-label, phase II study, the efficacy of rituximab on muscle and lung outcomes.

Mots clés

Adult, Autoantibodies, immunology, Creatine Kinase, blood, Female, Humans, Immunologic Factors, therapeutic use, Male, Middle Aged, Myositis, drug therapy, Rituximab, therapeutic use, Treatment Outcome, Vital Capacity, Young Adult

Référence

PLoS ONE. 2015 ;10(11):e0133702